SCHEMBL2330293

SCHEMBL2330293

CCCCN1C(=O)c2ccccc2C(C(=O)Nc2cccc(OC)c2)C1c1cccs1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.59
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
FFAR1 O14842 1/20 0.45
NPC1 O15118 2/20 0.45
ALDH1A1 P00352 5/20 0.44
MAPT P10636 3/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 2/20 0.43
NPSR1 Q6W5P4 3/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HTT P42858 1/20 0.42
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2334732 0.93 GAA (0.58) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2379561 0.92 GAA (0.60) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2337039 0.92 GAA (0.60) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2337755 0.92 GAA (0.60) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2379425 0.92 GAA (0.60) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2336299 0.92 GAA (0.60) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2330960 0.90 GAA (0.57) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2337765 0.89 GAA (0.58) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2330836 0.89 GAA (0.58) GAACYP2C9CYP2C19FFAR1NPC1
SCHEMBL2332755 0.88 GAA (0.58) GAACYP2C9CYP2C19NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US claimed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP claimed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 WO claimed
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP disclosed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 GAA 2348/4885CYP2C9 2412/4885CYP2C19 2392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.